Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Cell. 2023 Apr 13;186(8):1814-1814.e1. doi: 10.1016/j.cell.2023.02.039.
Therapeutic modalities that engage the immune system to recognize and eliminate cancer, known as cancer immunotherapy, has emerged as a distinct pillar of cancer therapy. Among the most promising treatment approaches are therapeutic vaccines, immune checkpoint blockade, bispecific T-cell engagers (BiTEs) and adoptive cell therapies. These approaches share a common mechanism of action, which is elicitation of a T-cell-based immune response, either endogenous or engineered, against tumor antigens, but interactions between the innate immune system, particularly antigen-presenting cells, and immune effectors also underlie the efficacy of cancer immunotherapies and approaches engaging these cells are also under development. To view this SnapShot, open or download the PDF.
治疗方法，通过免疫系统识别和消除癌症，称为癌症免疫疗法，已经成为癌症治疗的一个重要支柱。最有前途的治疗方法包括治疗性疫苗、免疫检查点阻断、双特异性 T 细胞衔接器（BiTE）和过继细胞疗法。这些方法具有共同的作用机制，即引发针对肿瘤抗原的基于 T 细胞的免疫反应，无论是内源性的还是工程化的，但先天免疫系统（特别是抗原呈递细胞）与免疫效应细胞之间的相互作用也构成了癌症免疫疗法的疗效基础，并且正在开发利用这些细胞的方法。要查看此快照，请打开或下载 PDF。
